Azacitidine: A new medication associated with Sweet syndrome

Tintle, Suzanne J.; Patel, V. C.; Ruskin, Andrea; Halasz, Charles L.

doi:10.1016/j.jaad.2010.06.032

Cited by 23 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SS is known to be triggered by certain medications, and in the given context, filgrastim and azacytidine are known to be associated. [13] Our patient did not receive filgrastim. She developed the first episode of SS, 9 days after the fourth cycle of azacytidine.…”

Section: Discussionmentioning

confidence: 74%

Histiocytoid Sweet syndrome: A rare variant of classic paraneoplastic dermatosis in relation to myelodysplastic syndrome - A case report

Dev

Agarwal

Khandpur

2020

Indian Journal of Medical and Paediatric Oncology

View full text Add to dashboard Cite

Histiocytoid Sweet syndrome is a distinctive variant of Sweet syndrome, which is more frequently associated with myelodysplastic syndromes (MDS) than the latter. We describe a 59-year-old woman, diagnosed with MDS 4 months back, who developed sudden onset of rapidly progressing multiple painful erythematous papules and plaques on bilateral forearms, without any systemic complaints. The biopsy revealed interstitial and perivascular infiltrate of immature histiocytoid cells (positive for CD 68, myeloperoxidase, lysozyme, and CD15), along with papillary dermal edema. The eruption resolved with topical steroids in 3 weeks.

show abstract

Section: Discussionmentioning

confidence: 74%

Histiocytoid Sweet syndrome: A rare variant of classic paraneoplastic dermatosis in relation to myelodysplastic syndrome - A case report

Dev

Agarwal

Khandpur

2020

Indian Journal of Medical and Paediatric Oncology

View full text Add to dashboard Cite

show abstract

“…In both cases reported by Jo and colleagues, the SS also responded to hypomethylating agents [Jo et al 2015]. It is also noteworthy that cases of drug-induced SS have been reported in the literature that occurred in response to the use of azacitidine for the treatment of MDS and leukemia [Tintle et al 2011; Trickett et al 2012; Bonazza et al 2015]. It has been reported that MLL-PTD is associated with increased global DNA methylation, which might explain the patient response to a hypomethylating agent [Whitman et al 2008; Kao et al 2015].…”

Section: Discussionmentioning

confidence: 99%

Sweet’s syndrome associated with clonal hematopoiesis of indeterminate potential responsive to 5-azacitidine

Yaghmour

Wiedower

Yaghmour

et al. 2016

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Sweet's syndrome (SS) is a rare condition characterized by the abrupt appearance of painful skin lesions due to neutrophilic dermal infiltration. Hematologic neoplasms, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs), have been commonly reported in association with SS. Clonal hematopoiesis of indeterminate potential (CHIP) is an emerging entity that is a precursor state to myeloid neoplasms. CHIP has not been previously associated with SS. We report the case of a 71-year-old man who presented with recurrent, painful edematous and erythematous papules and nodules for 18 months despite treatment with corticosteroids. He had normal blood counts, but a macrocytosis was noted (110 fl). Alternative causes of macrocytosis were ruled out. A skin biopsy confirmed a diagnosis of SS. Bone marrow biopsy specimen yielded a normal karyotype except for loss of the Y chromosome and equivocal morphologic findings. Polymerase chain reaction (PCR) and reverse transcription polymerase chain reaction (RT-PCR) of selected genes from the peripheral blood demonstrated a mixed lineage leukemia (MLL) partial tandem duplication (PTD) and sequence variant in CCAAT/ enhancer binding protein alpha (CEBPA). These findings were consistent with a diagnosis of CHIP. The patient was treated with 5-azacitidine and achieved a complete remission of his skin lesions and was able to discontinue corticosteroids. To our knowledge, this is the first report of a patient with recurrent SS associated with CHIP. In addition to other myeloid neoplasms like AML and MDS, CHIP should be considered as a potential etiology in cases of recurrent SS. Treatment with a hypomethylating agents such as azacitidine could also serve as an alternative to systemic corticosteroid therapy.

show abstract

“…Patients can also develop nodules, rash, pyoderma gangrenosum, and even Sweet syndrome or Nicolau syndrome at the injection site. 3,4 There is a potential for direct damage to skin that may result in skin necrosis. Fortunately, most skin reactions are self-limited and resolve spontaneously.…”

Section: Discussionmentioning

confidence: 99%

Severe phototoxic reaction secondary to subcutaneous 5-azacitidine

Keating

Dasanu

2016

J Oncol Pharm Pract

View full text Add to dashboard Cite

Phototoxicity occurs when the effects of sunlight and certain drugs converge at the skin level. Various pharmacologic agents have been linked to photosensitivity, including agents used in hematology and oncology. We describe herein a severe phototoxic response to subcutaneous 5-azacitidine. There are no previous reports of phototoxicity reactions to this agent in the published literature. As 5-azacitidine is frequently used to treat patients with myelodysplastic syndromes and acute myeloblastic leukemia, familiarity with this side effect is important for the medical and scientific community at large.

show abstract

Azacitidine: A new medication associated with Sweet syndrome

Cited by 23 publications

References 14 publications

Histiocytoid Sweet syndrome: A rare variant of classic paraneoplastic dermatosis in relation to myelodysplastic syndrome - A case report

Histiocytoid Sweet syndrome: A rare variant of classic paraneoplastic dermatosis in relation to myelodysplastic syndrome - A case report

Sweet’s syndrome associated with clonal hematopoiesis of indeterminate potential responsive to 5-azacitidine

Severe phototoxic reaction secondary to subcutaneous 5-azacitidine

Contact Info

Product

Resources

About